Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Product Development In Brief; Novartis Elinogrel, Acorda Fampridine

Executive Summary

Novartis targets elinogrel Phase III in 2010: After acquiring the anti-clotting compound elinogrel from Portola Pharmaceuticals in February, Novartis is planning to initiate Phase III trials of the drug in 2010, the Swiss drug maker says during first quarter sales and earnings update April 23. A large Phase III program will be required to evaluate safety, Global Head of Development, Pharma Trevor Mundel says. Elinogrel, which could have potential advantages over existing treatments like Bristol-Myers Squibb's Plavix (clopidogrel) as a reversible P2Y12 ADP receptor antagonist, currently is being studied in a 800-patient Phase II study. Novartis gained rights for the drug for $75 million upfront and $500 million in milestones (1"The Pink Sheet" DAILY, Feb. 12, 2009)

You may also be interested in...

FDA’s Refusal-To-File Slows Acorda’s Promising Niche MS Drug

Firm may need to refile NDA for mobility-boosting Fampridine-SR.

Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis

Deal could complicate venture investors' exit, though Portola thinks not – as another would-be partner eyes second lead product.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts